RecruitMe Clinical Trial

Prevention of de novo HCV with Antiviral HCV Therapy Post- liver and Post-kidney Transplant, Virologic Failure Sub-study
Prevention of Hepatitis C with Antiviral HCV Therapy After Liver and/or Kidney Transplant
Sponsor:University of California, San Francisco
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR8005
U.S. Government ID:NCT03619837
Contact: Cristina Falo, PhD: 212-305-3839 / cf2427@cumc.columbia.edu
Additional Study Information:

In this study, patients who are listed for a kidney or a liver transplant may be eligible for enrollment, asdetermined by their transplant doctors. The study is looking at patients who do not have hepatitis C virus (HCV) and provide their informed consent to receive a liver or kidney from a HCV positive donor. FDA approved medications that are used to treat HCV will be given to the study subjects shortly aftertransplant to protect them from developing the problems HCV can cause to the liver. This research study is being done to learn whether organ transplantation of livers and kidneys from donors who have HCV is safe and effective in recipients that do not have HCV.

Do You Qualify?
Are you 18 years of age or older?YesNo
Are you waitlisted for kidney or liver transplant?YesNo
Are you infected with Hepatitis C Virus (HCV)?YesNo
Submit
Cancel
Investigator
Elizabeth Verna, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Cristina Falo, PhD
Email: cf2427@cumc.columbia.edu
Phone: 212-305-3839